Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics develops investigational therapies for immune-mediated diseases, with news centered on its RASP modulator platform and late-stage ocular programs. Company updates commonly cover reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and next-generation RASP modulators including ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases.
Recurring developments include FDA interactions on the reproxalap New Drug Application, clinical and preclinical results, pipeline prioritization, manufacturing and regulatory disclosures, and research-and-development presentations. Aldeyra also reports conference participation and corporate updates tied to its Nasdaq-listed biotechnology issuer profile.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) will participate in two upcoming virtual investor conferences. CEO Todd C. Brady will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 1:10 p.m. ET, available for live streaming on the company's website. Additionally, Aldeyra executives will host one-on-one meetings with institutional investors at the A.G.P./Alliance Global Partners Virtual Healthcare Symposium on November 19, 2020. The firm focuses on innovative therapies for immune-mediated diseases, with lead compounds in clinical trials.
Aldeyra Therapeutics (Nasdaq: ALDX) will present its innovative approaches to ocular disease at the Eyecelerator 2020 Virtual Conference on November 6, 2020. President and CEO Todd C. Brady, M.D., Ph.D., will discuss clinical data on lead drug candidates, including 0.25% reproxalap ophthalmic solution and ADX-2191. Reproxalap is currently in Phase 3 trials for dry eye disease and allergic conjunctivitis, while ADX-2191 focuses on preventing proliferative vitreoretinopathy, a serious retinal disease. The conference aims to foster collaboration in ophthalmic innovation.
Aldeyra Therapeutics, Inc. (ALDX) has scheduled a conference call for November 5, 2020, at 8:00 a.m. ET to discuss its financial results for the quarter ending September 30, 2020. The call will provide an update on the company's corporate activities, focusing on its clinical-stage biotechnology projects aimed at treating immune-mediated diseases. Key compounds include reproxalap, ADX-629, ADX-2191, and ADX-1612, with ongoing Phase 3 trials in dry eye disease and proliferative vitreoretinopathy. A live webcast will be available on the company's investor relations page.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced new findings from a Phase 2 clinical trial of reproxalap, an ophthalmic solution for allergic conjunctivitis, presented at the AAO 2020 meeting. The trial demonstrated statistically significant improvements in ocular itching, tearing, and redness compared to the vehicle, supporting the drug's efficacy. The 0.25% concentration is moving to a Phase 3 trial, with top-line results anticipated in early 2021. No safety concerns were reported, highlighting reproxalap's potential in treating allergic conjunctivitis affecting over 1 billion globally.